The Regulator

330 million dollars: that is how much of the federal government’s own appropriated budget for patient-safety research is sitting unspent, after the Trump administration quietly stopped funding the agency built to keep American health care safe. Congress appropriated $345 million this fiscal year for the Agency for Healthcare Research and Quality, but the agency has spent less than $15 million on grants and has not issued a new one in over a year; a July 15, 2026 letter told researchers AHRQ was halting at least 104 grants, many aimed at improving patient safety, and agency staff has fallen from about 300 people in early 2025 to 74 today, a 75 percent reduction. AHRQ’s past work includes hospital-infection-prevention programs credited with saving an estimated 20,500 lives and 7.7 billion dollars between 2014 and 2017; the Society for General Internal Medicine has sued over the funding halt, and the U.S. Preventive Services Task Force, which AHRQ supports, has a meeting scheduled for late August. An HHS spokesperson said AHRQ “is strengthening its grants process, reviewing agency work for quality, aligning with its statutory mission.” Confidence: Medium. This account rests on CBS News and KFF Health News reporting that quotes HHS’s own spokesperson directly and cites the agency’s July 15 letter to researchers; this run could not independently retrieve AHRQ’s letter or a primary HHS budget document. Sources: Trump administration has quietly throttled an agency devoted to the safety of American healthcare, CBS News, Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare, KFF Health News.

25 drugs, from 13 pharmaceutical companies: that is the expanded footprint of the government’s own rebate-style 340B drug discount program, announced the same week a federal appeals court ruled drugmakers cannot run their own version of the same idea without permission first. The Health Resources and Services Administration posted a Federal Register notice July 31, 2026 announcing a revised 340B Rebate Model Pilot Program, HRSA’s voluntary program letting participating manufacturers pay hospitals and clinics back for the 340B discount after purchase rather than applying it up front; the pilot grows from the roughly 10 drugs and eight manufacturers HRSA first proposed to as many as 25 products from 13 companies. Ten days earlier, on July 21, 2026, the U.S. Court of Appeals for the District of Columbia Circuit ruled that Novartis, Johnson and Johnson Health Care Systems, Bristol Myers Squibb and Eli Lilly cannot impose their own, separate rebate models on 340B covered entities without the HHS secretary’s approval, a distinct dispute that nonetheless underscores how contested the rebate-versus-upfront-discount question has become; hospitals and community health centers have opposed rebate models generally, since paying back the discount later strains cash flow for safety-net providers. Confidence: Medium. Trade press coverage corroborates the expanded drug count and the ruling’s holding, but this run could not independently extract the full text of HRSA’s July 31 Federal Register notice, which returned an access block. Sources: Notice Regarding 340B Rebate Model Pilot Program, Federal Register, Court rules that companies may not impose 340B rebate model without HHS approval, American Hospital Association.

80 hours a month: that is the new work, school or volunteering requirement most Medicaid expansion enrollees must now start documenting, after a federal judge refused to pause the rule two days before it took legal effect. The Centers for Medicare and Medicaid Services’ interim final rule defining which beneficiaries count as “medically frail” and exempt from the new community-engagement requirement took legal effect July 31, 2026, the same day its own public comment period closed, two days after U.S. District Judge Richard G. Stearns denied a preliminary injunction sought by Massachusetts and 25 other states and the District of Columbia in Commonwealth of Massachusetts et al. v. Oz et al. States must now notify beneficiaries about the requirement by August 31, 2026, and enrollees must start complying January 1, 2027; the underlying lawsuit over whether CMS illegally narrowed the medically-frail exemption, including excluding people in stable substance-use-disorder recovery of five years or more, continues toward a hearing on the merits. Confidence: High on the rule’s effective date and the litigation timeline, corroborated directly by STAT News’s reporting on the docket; Medium on how many beneficiaries the narrowed exemption affects, since CMS has not published its own estimate. Sources: Federal Medicaid Work Rule Takes Legal Effect Friday as a Judge Weighs Whether to Pause It, Medical Daily, Commonwealth of Massachusetts et al. v. Oz et al., Georgetown University Health Care Litigation Tracker.

10,000 dollars a day: that is the civil penalty independent and physician-office laboratories now face for missing a Medicare data deadline that passed at 11 p.m. Eastern last night. The Centers for Medicare and Medicaid Services required applicable clinical laboratories, meaning independent labs and physician-office labs that are not hospital-based, to report their private-payer rate and volume data for services performed January through June 2025 by July 31, 2026 under the Protecting Access to Medicare Act’s Clinical Laboratory Fee Schedule reporting rules; a lab that fails to report, or that misrepresents or omits required data, faces a civil monetary penalty of up to $10,000 per day for each violation. The data collected in this window will set Original Medicare’s laboratory payment rates for calendar years 2027 through 2029, meaning which labs reported, and what they reported, will shape lab reimbursement nationally for three years. Confidence: High. CMS’s own FAQ document and hospital-association guidance describe the deadline and penalty directly. Sources: Private Payor Rate-Based CLFS, Frequently Asked Questions, Centers for Medicare and Medicaid Services, Hospital Clinical Lab Fee Schedule Data Is Due to CMS by July 31, Kentucky Hospital Association.

45 million dollars: that is what a New York nursing home chain already paid for defrauding Medicaid and neglecting residents, and it is still violating the settlement that was supposed to fix it, with the state’s own monitoring window closing at the end of this week. New York Attorney General Letitia James secured a $45 million settlement in November 2024 with Centers Health Care, a 37-facility nursing home chain, and its owners, Daryl Hagler and Kenneth Rozenberg, after accusing them of pocketing more than $80 million in Medicaid funds meant for resident care while running chronically understaffed, neglectful facilities; the deal installed an independent health monitor in July 2023 to oversee the chain through at least July 31, 2026. A report this week found the chain still in violation of that settlement, including a March 2026 inspection at a Finger Lakes facility that found two residents in rooms so cold they risked hypothermia, one actively shivering and another covered only by a sheet while the heating unit blew cold air on a day when the outside temperature averaged 23 degrees. Confidence: dropped. The Attorney General’s own 2024 settlement announcement confirms the fine, chain, owners and monitoring period directly, but this run could not independently retrieve the state’s July 2026 monitoring report, so the violation and inspection details rest on New York Focus’s reporting. Sources: Nursing Home Chain Violates $45M Settlement With New York, New York Focus, Attorney General James Secures $45 Million and Delivers Major Reforms to Four Nursing Homes Following Significant Financial Fraud and Resident Neglect, New York Attorney General.